Vera Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VERA Nasdaq 2830 veratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vera Therapeutics, Inc.

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results - Oct 22nd, 2026 7:04 pm
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine - Oct 22nd, 2026 8:05 am
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast - Oct 20th, 2026 6:00 am
Do Vera Therapeutics' (VERA) High-Profile IgAN Data Show Durable Moat or Crowded Mechanism Risk? - Oct 8th, 2026 9:15 am
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 2nd, 2026 2:05 pm
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 - Oct 2nd, 2026 7:24 am
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? - Sep 24th, 2026 8:27 am
2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be Brewing - Sep 17th, 2026 11:58 am
Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints - Sep 17th, 2026 12:12 am
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next - Sep 15th, 2026 7:51 pm
Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened? - Sep 15th, 2026 2:40 pm
Vera set up for full approval for Trutakna in IgAN with Phase III win - Sep 15th, 2026 10:39 am
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results - Sep 15th, 2026 10:03 am
Top Midday Stories: Waystar Reportedly Mulling Potential Sale; Intel-Backed Altera Says Parent Company Files Confidentially for IPO - Sep 15th, 2026 9:42 am
Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints - Sep 15th, 2026 7:37 am
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday - Sep 15th, 2026 7:12 am
VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4 - Sep 15th, 2026 7:08 am
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy - Sep 15th, 2026 4:30 am
Vera Therapeutics to Participate at Upcoming Investor Conferences - Sep 1st, 2026 5:30 am